ライフサイエンスコーパス: platelet-activating

1 A physiological agonist, ADP, stimulates platelets, activating alpha(IIb)beta(3).

2 Platelet-activating anti-protamine-heparin antibodies sh

3 Seven patients had platelet-activating, anti-protamine-heparin antibodies a

4 prothrombotic adverse drug effect induced by platelet-activating antibodies against multimolecular co

5 eparin reexposure can be safely performed if platelet-activating antibodies are no longer detectable

6 thrombocytopenia (HIT) can be appropriate if platelet-activating antibodies are no longer detectable.

7 a novel, unexpected, PS backbone-dependent, platelet-activating effect of nucleotide-based drug cand

8 mechanisms may contribute to the unexpected platelet-activating effects of pharmaceutical integrin a

9 The mechanism by which UFH elicits these platelet-activating effects, however, is not well unders

10 ceptor glycoprotein VI (GPVI) mediates these platelet-activating effects.

11 els for 1 hour and intraluminal injection of platelet activating factor (50 micro/kg).

12 The platelet activating factor (PAF) acetyl hydrolase 1b (Pa

13 alyzes the hydrolytic inactivation of plasma platelet activating factor (PAF) and is also known as PA

14 Platelet activating factor (PAF) and PAF-like lipids ind

15 as well as resveratrol and quercetin, on the platelet activating factor (PAF) biosynthetic enzymes, a

16 plexed with the physiological ligand GM2 and platelet activating factor (PAF) have shown binding at t

17 Platelet activating factor (PAF) interacts with cell sur

18 Platelet activating factor (PAF) is a potent lipid autoc

19 tenuate the permeability increase induced by platelet activating factor (PAF) or bradykinin.

20 th BN52021, WEB-2170, and WEB-2086 (specific platelet activating factor (PAF) receptor antagonists),

21 Both LPS and BLP stimulated the synthesis of platelet activating factor (PAF), a potent lipid mediato

22 rved that tumor necrosis factor (TNF)-alpha, platelet activating factor (PAF), and lipopolysaccharide

23 rmyl-methionyl-leucyl-phenylalanine (fMLP)), platelet activating factor (PAF), leukotriene B4 (LTB(4)

24 mbination with uridine 5'-diphosphate (UDP), platelet activating factor (PAF), or lysophosphatidic ac

25 incubated in H2O2 (70 micromol/L, 2 hours), platelet activating factor (PAF), prostaglandin E2 (PGE2

26 ion and chemoattraction, Mig potently blocks platelet activating factor (PAF)- and leukotriene B4 (LT

27 A crystal structure of GM2-AP complexed with platelet activating factor (PAF).

28 se, neutrophil activation in the presence of platelet activating factor (PAF).

29 ed for lysophosphatidylcholine (lysoPCh) and platelet activating factor (PAF).

30 Low platelet activating factor acetyl hydrolase activity was

31 oluble tumor necrosis factor receptor I, and platelet activating factor acetyl hydrolase.

32 with the HDL-associated enzymes paraoxonase, platelet activating factor acetylhydrolase (PAF), and gl

33 nts, the most potent effect was observed for platelet activating factor acetylhydrolase alpha (Paf-AH

34 mesangial cell line induced upregulation of platelet activating factor and the fibrotic marker TGF-b

35 d to surrogate PMNs respond to activation by platelet activating factor by initiating translation and

36 regation was blocked using a monoclonal anti-platelet activating factor receptor (PafR) antibody and

37 ine, an H1R antagonist, blocked EAE, and the platelet activating factor receptor antagonist CV6209 re

38 creased adherence mediated by binding to the platelet activating factor receptor on epithelial cells.

39 d receptor-1, protease activated receptor-3, platelet activating factor receptor, and factor V.

40 D synthase, histamine receptor type 1 (H1R), platelet activating factor receptor, Ig Fc epsilon recep

41 rotein is rapidly synthesized in response to platelet activating factor under the control of a specia

42 ng receptors for chemokines, PGs, histamine, platelet activating factor, and anaphylatoxin.

43 ith N-formyl-methionyl-leucyl-phenylalanine, platelet activating factor, and leukotriene B4 was phosp

44 d immunoglobulins (IgG, IgA), cytokines with platelet activating factor, calcium ionophore, or phorbo

45 NET formation after stimulation with platelet activating factor, ionomycin, or phorbol 12-myr

46 ogen synthase kinase 3beta inhibitor, blocks platelet activating factor-induced activation of glycoge

47 ulation of a G-protein coupled receptor with platelet activating factor.

48 significantly inhibited the biosynthesis of platelet activating factor.

49 hingomyelin (SM) to ceramide and inactivates platelet activating factor.

50 y alcohols, which are possible precursors of platelet activating factor.

51 Platelet-activating factor (1-alkyl-2-acetyl-3-glyceroph

52 Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycer

53 Platelet-activating factor (PAF [1-O-alkyl-2-acetyl-sn-g

54 The plasma form of platelet-activating factor (PAF) acetylhydrolase (PAF-AH

55 Human plasma platelet-activating factor (PAF) acetylhydrolase functio

56 low density lipoprotein and comigrates with platelet-activating factor (PAF) acetylhydrolase on KBr

57 The platelet-activating factor (PAF) acetylhydrolase SsE pro

58 the PAFAH1B2 and PAFAH1B3 subunits of type I platelet-activating factor (PAF) acetylhydrolase, a phos

59 UV-induced keratinocyte-derived platelet-activating factor (PAF) activates mast cell mig

60 idized glycerophosphocholines (Ox-GPCs) with platelet-activating factor (PAF) activity produced non-e

61 uction of glycerophosphocholines that act as platelet-activating factor (PAF) agonists.

62 er short-chained phospholipids--inflammatory platelet-activating factor (PAF) and apoptotic oxidative

63 genesis and photoimmune suppression, such as platelet-activating factor (PAF) and serotonin (5-HT) re

64 Platelet-activating factor (PAF) and structurally-relate

65 GS4, also blocked phosphorylation of PAFR by platelet-activating factor (PAF) and, unexpectedly, by p

66 Species related to platelet-activating factor (PAF) and/or lyso-phosphatidy

67 Treatment with platelet-activating factor (PAF) antagonists also reduce

68 Over the past few years, the role of platelet-activating factor (PAF) as a potent mediator in

69 We used platelet-activating factor (PAF) as a proinflammatory ag

70 r wild-type control as experimental animals, platelet-activating factor (PAF) at 10(-7) m as the test

71 Platelet-activating factor (PAF) causes wheal and flare

72 at cigarette smoking leads to an increase in platelet-activating factor (PAF) content and PAF recepto

73 ured spleen and liver cytokine responses and platelet-activating factor (PAF) content in mice given C

74 -2) regulate surfactant protein-A (SP-A) and platelet-activating factor (PAF) expression, which incre

75 ittle, if any, role in neutrophil priming by platelet-activating factor (PAF) for OpZ-dependent respo

76 Platelet-activating factor (PAF) has been shown to affec

77 In the current study, the role of platelet-activating factor (PAF) in combination with tum

78 t studies have implicated the lipid mediator platelet-activating factor (PAF) in UVB-mediated systemi

79 models of LE that the phospholipid mediator platelet-activating factor (PAF) increases in LE and tha

80 Platelet-activating factor (PAF) increases permeability

81 It is known that platelet-activating factor (PAF) induces severe endothel

82 Evidence suggests that platelet-activating factor (PAF) is a mediator in inflam

83 Platelet-activating factor (PAF) is a mediator of inflam

84 Platelet-activating factor (PAF) is a naturally occurrin

85 Platelet-activating factor (PAF) is a phospholipid media

86 Platelet-activating factor (PAF) is a phospholipid with

87 In this study, we demonstrate that platelet-activating factor (PAF) is a potent inducer of

88 Platelet-activating factor (PAF) is a potent lipid media

89 Platelet-activating factor (PAF) is a potent phospholipi

90 Platelet-activating factor (PAF) is a potent proinflamma

91 Platelet-activating factor (PAF) is a potent proinflamma

92 Platelet-activating factor (PAF) is a potent proinflamma

93 Platelet-activating factor (PAF) is a potent, bioactive

94 Platelet-activating factor (PAF) is a powerful proinflam

95 Platelet-activating factor (PAF) is a proinflammatory ph

96 Because platelet-activating factor (PAF) is a proximal mediator

97 Platelet-activating factor (PAF) is an important mediato

98 The phospholipid platelet-activating factor (PAF) is an important mediato

99 Platelet-activating factor (PAF) is implicated in the ca

100 Because the lipid mediator of inflammation, platelet-activating factor (PAF) is released by UV-irrad

101 Animal models show that the receptor for platelet-activating factor (PAF) is responsible for many

102 Although the lipid mediator platelet-activating factor (PAF) is synthesized in respo

103 Although the lipid mediator platelet-activating factor (PAF) is synthesized in respo

104 Platelet-activating factor (PAF) mediates an array of bi

105 Animal and human data show that platelet-activating factor (PAF) mediates the life-threa

106 ry potential of the proinflammatory mediator platelet-activating factor (PAF) on the subcellular dist

107 urvival after anaphylaxis, administration of platelet-activating factor (PAF) or histamine, and expos

108 th Kindlin-2 siRNA showed enhanced basal and platelet-activating factor (PAF) or lipopolysaccharide-s

109 esulted from inhibitory signals generated by platelet-activating factor (PAF) or oxidized LDL that ac

110 ncreased AA and PGE2 release, accompanied by platelet-activating factor (PAF) production.

111 We hypothesize that platelet-activating factor (PAF) receptor (PAFR) ligatio

112 LAU-0901, a novel platelet-activating factor (PAF) receptor antagonist, is

113 regation was inhibited by antagonists of the platelet-activating factor (PAF) receptor but not inhibi

114 tor and that antagonists of 5-HT(2A) and the platelet-activating factor (PAF) receptor can block cis-

115 f intracellular Leishmania, we surmised that platelet-activating factor (PAF) receptor had a signific

116 Activation of the platelet-activating factor (PAF) receptor leads to a dec

117 onist of the PTX-sensitive G protein-coupled platelet-activating factor (PAF) receptor, blocked the a

118 Corneal stromal myofibroblasts express the platelet-activating factor (PAF) receptor, but its role

119 ba extracts and are known antagonists of the platelet-activating factor (PAF) receptor.

120 Ginkgolides are known antagonists of the platelet-activating factor (PAF) receptor.

121 igated for their ability to bind to a cloned platelet-activating factor (PAF) receptor.

122 These studies examined the role of the platelet-activating factor (PAF) signaling system in UVB

123 Previously, we reported that platelet-activating factor (PAF) stimulates higher G pro

124 ne suppression are the binding of UV-induced platelet-activating factor (PAF) to its receptor and the

125 and the proinflammatory glycerophospholipid platelet-activating factor (PAF) were markedly reduced i

126 cell types with respect to the metabolism of platelet-activating factor (PAF), a biologically active

127 s by exploiting molecular mimicry to degrade platelet-activating factor (PAF), a host-derived inflamm

128 Platelet-activating factor (PAF), a phospholipid second

129 We analyzed the effect of platelet-activating factor (PAF), a potent phospholipid

130 Recent studies suggest that the action of platelet-activating factor (PAF), a potent phospholipid

131 Platelet-activating factor (PAF), a potent phospholipid

132 ated endocytosis (CME), we hypothesized that platelet-activating factor (PAF), an effective chemoattr

133 in corneal epithelial cells stimulated with platelet-activating factor (PAF), and interferes with th

134 UVB radiation generates the lipid mediator, platelet-activating factor (PAF), as well as oxidized ph

135 nergistic signaling induced by serotonin and platelet-activating factor (PAF), but not histamine.

136 Leu-Phe (fMLP), adenosine diphosphate (ADP), platelet-activating factor (PAF), interleukin-8 (IL-8),

137 shown that the lipid inflammatory mediator, platelet-activating factor (PAF), synthesized by activat

138 mbrane inhibits hyperpermeability induced by platelet-activating factor (PAF), VEGF in ECV-CD8eNOSGFP

139 e calcium entry (SOCE) following the initial platelet-activating factor (PAF)-induced release of Ca(2

140 Degrading platelet-activating factor (PAF)-like lipids in L5 by a

141 roduction of prostaglandin I(2) (PGI(2)) and platelet-activating factor (PAF).

142 mediators, including adhesion molecules and platelet-activating factor (PAF).

143 is mediated, in part, by the lipid mediator platelet-activating factor (PAF).

144 rat small intestine and is down-regulated by platelet-activating factor (PAF).

145 P) protects mice from lethal challenges with platelet-activating factor (PAF).

146 rete the inflammatory phospholipid mediator, platelet-activating factor (PAF).

147 phospholipids and the inflammatory mediator platelet-activating factor (PAF).

148 eparations with or without pretreatment with platelet-activating factor (PAF).

149 secrete the lipid mediator of inflammation, platelet-activating factor (PAF).

150 reduces neutrophil recruitment by targeting platelet-activating factor (PAF).

151 Among the proinflammatory mediators, platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-g

152 diated responses, RGS4 and the receptors for platelet-activating factor (PAFR), formylated peptides (

153 holine (ChoP), a ligand for the receptor for platelet-activating factor (rPAF).

154 gulation of expression of the plasma form of platelet-activating factor acetylhydrolase (PAF AH) in t

155 Platelet-activating factor acetylhydrolase (PAF-AH) is a

156 The enzyme platelet-activating factor acetylhydrolase (PAF-AH) rapi

157 or was inactivated by alkaline hydrolysis or platelet-activating factor acetylhydrolase (PAF-AH) trea

158 the possibility that the activity represents platelet-activating factor acetylhydrolase (PAF-AH), an

159 We report that platelet-activating factor acetylhydrolase (PAFAH) Ib, c

160 t that the cytoplasmic PLA(2) enzyme complex platelet-activating factor acetylhydrolase (PAFAH) Ib, w

161 fective milk containing diminished levels of platelet-activating factor acetylhydrolase (PAFAH).

162 Platelet-activating factor acetylhydrolase (PLA2G7) is a

163 Platelet-activating factor acetylhydrolase 1B1 (LIS1), a

164 lycopene), and antioxidant enzyme activity (platelet-activating factor acetylhydrolase [PAF-AH] and

165 A recent report demonstrates that plasma platelet-activating factor acetylhydrolase activity incr

166 om allergy, such as suggesting that baseline platelet-activating factor acetylhydrolase activity leve

167 Plasma platelet-activating factor acetylhydrolase becomes progr

168 lesterolemic human plasma with a recombinant platelet-activating factor acetylhydrolase completely ab

169 izygous mutations in the human gene encoding platelet-activating factor acetylhydrolase IB subunit al

170 The activities of paraoxonase and platelet-activating factor acetylhydrolase in HDL decrea

171 imal study, transfection of tumor cells with platelet-activating factor acetylhydrolase inhibited tum

172 nt controversy over whether paraoxonase 1 or platelet-activating factor acetylhydrolase is responsibl

173 rpose of this study was to determine whether platelet-activating factor acetylhydrolase Sse and strep

174 creened by enzymatic assays for SpeB and the platelet-activating factor acetylhydrolase Sse, and a ne

175 coding complement component receptor 2/CD21, platelet-activating factor acetylhydrolase, and oxidized

176 tions in the relative levels of paraoxonase, platelet-activating factor acetylhydrolase, ceruloplasmi

177 n-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, is a new ris

178 lation and elongation protein zeta-1 (FEZ1), platelet-activating factor acetylhydrolase, isoform Ib,

179 e inconclusive in determining whether plasma platelet-activating factor acetylhydrolase, or lipoprote

180 nzymes, BChE and a new extracellular form of platelet-activating factor acetylhydrolase, PAFAH1b2.

181 ated phospholipase A2 (Lp-PLA2), also called platelet-activating factor acetylhydrolase, plays in ath

182 Lp-PLA2, also known as platelet-activating factor acetylhydrolase, rapidly clea

183 hospholipase A(2) (Lp-PLA(2)), also known as platelet-activating factor acetylhydrolase.

184 Platelet-activating factor acetylhydrolases (PAF-AHs) ar

185 Finally, Tat and platelet-activating factor also increased neuronal vesic

186 In hippocampal slices exposed to a stable platelet-activating factor analogue, tetanic stimulation

187 As platelet-activating factor and HPC share structural semb

188 on anaphylaxis suggest an important role for platelet-activating factor and its relationship to the n

189 flammatory mediators (tumor necrosis factor, platelet-activating factor and prostaglandins), studies

190 locked by a combination of antihistamine and platelet-activating factor antagonist (but neither alone

191 Tsujimura et al. report that the release of platelet-activating factor by basophils stimulated with

192 se in cytosolic Ca2+ whereas the addition of platelet-activating factor did.

193 surfactant phospholipids and biosynthesis of platelet-activating factor in noninflammatory remodeling

194 -third, suggesting a role for toxin-produced platelet-activating factor in this process.

195 Using our model, we also show that platelet-activating factor is a crucial mediator of both

196 ceptor antagonists, or overexpression of the platelet-activating factor metabolizing enzyme acetylhyd

197 depletion by the G protein-coupled agonists platelet-activating factor or fMLP, but abolished agonis

198 tional state, and subsequent activation with platelet-activating factor or formyl-methionyl-leucyl-ph

199 Furthermore, platelet-activating factor or interleukin 8 acted in con

200 ormally sensitive to substance P, but not to platelet-activating factor or serotonin, suggesting that

201 Under the same experimental conditions, platelet-activating factor primed neutrophils for supero

202 factor, the ability of alpha-toxin to induce platelet-activating factor production was assessed, and

203 eir ability to generate oxidized lipids with platelet-activating factor receptor (PAF-R) agonist acti

204 by generating oxidized lipid agonists of the platelet-activating factor receptor (PAF-R).

205 er of melanoma metastasis, via activation of platelet-activating factor receptor (PAFR) and cAMP-resp

206 dditional recognition system mediated by the platelet-activating factor receptor (PAFr) and directed

207 e hypothesis that influenza up-regulates the platelet-activating factor receptor (PAFr) and thereby p

208 Inhibitors of platelet-activating factor receptor (PAFR) blocked LTA-

209 We have previously shown that the Platelet-Activating Factor Receptor (PAFR) engagement in

210 The platelet-activating factor receptor (PAFr) has been sugg

211 hibitors identified a prominent role for the platelet-activating factor receptor (PAFr) in hypoxia-as

212 Platelet-activating factor receptor (PAFR) is a G protei

213 Platelet-activating factor receptor (PAFr) mediates pneu

214 f synaptic activity in a manner dependent on platelet-activating factor receptor (PAFR) signaling.

215 polymeric immunoglobulin receptor (pIgR) and platelet-activating factor receptor (PAFr) to attach and

216 iciency in interleukin 1alpha (IL-1alpha) or platelet-activating factor receptor (PAFR), an important

217 of A. baumannii binds to A549 cells through platelet-activating factor receptor (PAFR), resulting in

218 Moreover, expression of platelet-activating factor receptor (PAFR), which is kno

219 nvolved in immune responses include CD36 and platelet-activating factor receptor (PAFR).

220 r airway cells is mediated by host-expressed platelet-activating factor receptor (PAFR).

221 oupled receptors and excluded key candidates platelet-activating factor receptor and CCR5.

222 experiments revealed that L5 signals through platelet-activating factor receptor and lectin-like oxid

223 s demonstrate the differential expression of platelet-activating factor receptor and TLR-4 in uterine

224 nti-eotaxin and anti-RANTES mAbs, but not by platelet-activating factor receptor antagonists (CV6209,

225 Pretreatment of HaCaT cells with platelet-activating factor receptor antagonists, or over

226 Platelet-activating factor receptor blockade protected s

227 tion was assessed, and whether the epidermal platelet-activating factor receptor could augment toxin-

228 ctive effect resulted in part from decreased platelet-activating factor receptor expression on endoth

229 antibody or therapeutic agents that modulate platelet-activating factor receptor expression, may conf

230 stry studies demonstrate the presence of the platelet-activating factor receptor in both endometrial

231 nally, retroviral-mediated expression of the platelet-activating factor receptor into the platelet-ac

232 Anaphylaxis was inhibited by platelet-activating factor receptor or histamine recepto

233 milar involvement for an unrelated GPCR (the platelet-activating factor receptor), indicating that it

234 Bacterial lipoteichoic acid activates the platelet-activating factor receptor, which is G protein-

235 rom the international phase III trial of the platelet-activating factor receptor-antagonist Lexipafan

236 platelet-activating factor receptor into the platelet-activating factor receptor-negative epithelial

237 ent studies used model systems consisting of platelet-activating factor receptor-positive and -negati

238 lin receptor, or cell wall phosphorylcholine/platelet-activating factor receptor.

239 signaling can be augmented via the epidermal platelet-activating factor receptor.

240 holine residues on pneumococcal cell wall to platelet-activating factor receptor.

241 hil, macrophage, and neutrophil secretion of platelet-activating factor subsequent to FcgammaR stimul

242 of PMN cationic entry after thapsigargin or platelet-activating factor suggested that SOCE occurs th

243 Lysophosphatidylcholine and lyso-platelet-activating factor were also associated directly

244 as prior exposure to a p38-activating agent (platelet-activating factor) diminished the TNFalpha-indu

245 some of these peptides (eg, endothelin-1 and platelet-activating factor) has decreased mortality and

246 nt chemicals (bradykinin, capsaicin, low pH, platelet-activating factor), whereas Adelta-fibres are r

247 that were 50-70% of those induced by 100 nM platelet-activating factor, a positive control.

248 toxic injury via activation of receptors for platelet-activating factor, a proinflammatory signaling

249 tic oxidatively truncated phospholipids, and platelet-activating factor, a remarkably potent and plei

250 ory cellular metabolite up-regulated by Tat, platelet-activating factor, also induced oxidative stres

251 We report that platelet-activating factor, an inflammatory phospholipid

252 ory G protein-coupled chemoattractants fMLP, platelet-activating factor, and IL-8 elicit unique patte

253 Lysophosphatidylcholine, lyso-platelet-activating factor, and several phospholipid fat

254 production induced by TNF-alpha, GM-CSF, and platelet-activating factor, and this loss of pyk2 activi

255 e mediated by the autocrine activity, not of platelet-activating factor, but rather of endogenous CCR

256 irway eosinophils to chemoattractants (FMLP, platelet-activating factor, CCL11, CCL5, CXCL8) with res

257 cellular calcium concentration stimulated by platelet-activating factor, fMLP, and SP-G.

258 duction of prostaglandins, leukotrienes, and platelet-activating factor, is present in EAE lesions.

259 merous chemoattractants, such as chemokines, platelet-activating factor, or FMLP, through a process k

260 ls with G protein-coupled receptor agonists, platelet-activating factor, or FMLP.

261 mediators, including TNF-alpha, GM-CSF, and platelet-activating factor, overcomes the adhesion-media

262 -alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor, PAF) and the generation of 2

263 phils were treated with fMLP with or without platelet-activating factor, PMA alone, or tumor necrosis

264 nitiates the biosynthesis of eicosanoids and platelet-activating factor, potent mediators of inflamma

265 ity, we found that histamine, serotonin, and platelet-activating factor, small molecule vascular perm

266 lus for the synthesis for the lipid mediator platelet-activating factor, the ability of alpha-toxin t

267 Depletion of basophils and blockade of platelet-activating factor, the key components of the Ig

268 ructurally diverse neutrophil-priming agents platelet-activating factor, TNF-alpha, and the substance

269 5-hydroxytryptamine), platelet factor 4, and platelet-activating factor, which specifically stimulate

270 lpha-toxin resulted in significant levels of platelet-activating factor, which were approximately 50%

271 l, lipid mediators lysophosphatidic acid and platelet-activating factor, whose signals are implicated

272 via CD14-, NF-kappaB-, and p44/42-dependent, platelet-activating factor-independent activation of the

273 otected primary astrocytes from H(2)O(2)- or platelet-activating factor-induced apoptosis.

274 In ADSA lymphoblasts, platelet-activating factor-induced Ca(2+) mobilization w

275 ependent manner, LXs significantly inhibited platelet-activating factor-induced increases in leukocyt

276 Following platelet-activating factor-induced shock, MK886 increase

277 gosine blocks thapsigargin-, ionomycin-, and platelet-activating factor-mediated SOCE despite normal

278 hown that the protein acts primarily as lyso-platelet-activating factor-phospholipase C.

279 ed priming of this response by TNF-alpha and platelet-activating factor.

280 is induced by administration of histamine or platelet-activating factor.

281 rmation was also reversed by the addition of platelet-activating factor.

282 trates for the production of eicosanoids and platelet-activating factor.

283 -containing lipids, such as lyso-PC, PC, and platelet-activating factor.

284 2-AG) are unaffected by LPS but increased by platelet-activating factor.

285 human epithelial cells via the receptor for platelet-activating factor.

286 ector cells, and the mediators histamine and platelet-activating factor.

287 ins in whole blood and dampened responses to platelet-activating factor.

288 uding vascular endothelial growth factor and platelet-activating factor; by contrast, endothelial cel

289 owing to elevated levels of pro-inflammatory platelet-activating factors.

290 Immunoassays fail to discriminate platelet-activating from nonpathogenic antibodies.

291 action of unusual pathogenesis that features platelet-activating immunoglobulin G antibodies.

292 signaling cascade and inhibits virtually all platelet-activating key mechanisms.

293 existence of a second alpha-thrombin-induced platelet-activating pathway, dependent on GP Ib, which d

294 f antibodies with strong heparin-independent platelet-activating properties are formed.

295 isposed to forming recurrent antibodies with platelet-activating properties.

296 bodies exhibiting strong heparin-independent platelet-activating properties.

297 tin-like receptor 2 (CLEC-2) is an essential platelet-activating receptor in hemostasis and thrombosi

298 C-type lectin-like receptor 2 are essential platelet activating receptors in hemostasis and thrombo-

299 omponents that specifically target different platelet-activating receptors such as the collagen-bindi

300 rades adenosine 5'-diphosphate (ADP), a main platelet activating/recruiting agent.